Market Place
Sourcing Support
All News #Library
Biotech
Almirall, BSC Expand Collaboration to Boost Dermatology R&D
13 Apr 2026 //
PHARMIWEB
Lebrikizumab Shows 4-Year Control In Atopic Dermatitis
27 Mar 2026 //
BUSINESSWIRE
Almirall 17th Skin Academy Highlights Advances In Skin Diseases
23 Mar 2026 //
PHARMIWEB
Almirall Sustains Growth Momentum With 12.8% Net Sales Increase
10 Nov 2025 //
PHARMIWEB
Almirall Advances Skin Science at EADV 2025 for Holistic Care
17 Sep 2025 //
PHARMAWEB
Centrient opens Innovation Lab in Barcelona`s Product Development
21 Oct 2024 //
PRESS RELEASE
New Data Almirall`s Ebglyss Shows 3-Year Atopic Dermatitis
25 Sep 2024 //
BUSINESSWIRE
Almirall To Present New Psoriasis Atopic Dermatitis Data
23 Sep 2024 //
BUSINESSWIRE
NICE Recommends Ebglyss For Atopic Dermatitis In NHS England
10 Jul 2024 //
BUSINESSWIRE
Almirall`s Ilumetri Restores Patient Wellbeing in Severe Plaque Psoriasis
28 Jun 2024 //
BUSINESSWIRE
Almirall Initiates First Phase I Clinical Study of ALM223
21 Dec 2023 //
BUSINESSWIRE
Almirall: 80% of patients with atopic dermatitis maintained clear skin with lebrikizumab
20 Oct 2023 //
BUSINESSWIRE
Almirall`s Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe AD
13 Oct 2023 //
BUSINESSWIRE
Almirall`s Ilumetri® (tildrakizumab) Significantly Improves Wellbeing
11 Oct 2023 //
BUSINESSWIRE
EBGLYSS Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
15 Sep 2023 //
BUSINESSWIRE
Almirall: Ilumetri improved the wellbeing of patients with plaque psoriasis
07 Jul 2023 //
BUSINESSWIRE
Almirall: Up to 73% of Atopic Der Patients Taking Lebrikizumab Had Improved
01 May 2023 //
BUSINESSWIRE
Almirall: (NEJM) and the (BJD) Publish Ph3 Data Evaluating lebrikizumab Efficacy
31 Mar 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.